Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with severe aortic stenosis at extreme surgical risk and an acceptable alternative to surgical aortic valve replacement in patients at high risk. Despite a growing amount of evidence in support of TAVI there remain important limitations and recognized complications. The SADRA Lotus Valve System is a novel TAVI device capable of allowing full repositionability and retrievability, which may address some of the first generation limitations.